How to Use This Guide

Medical Patient Guide

Medical cannabis helps some people with some conditions, and the strength of the science varies a lot from one condition to the next. This guide tells you honestly what the research shows for each condition, so you and your practitioner can decide together whether cannabis is worth trying.

What the Evidence Ratings Mean

Medical cannabis is a treatment option, not a cure. It usually works best alongside your regular care, not in place of it. Never stop or change a prescribed medicine without talking to the clinician who prescribed it.

Rating What it means for you
Strong

Several good-quality studies agree, and in most cases there is an FDA-approved cannabinoid medicine for this use.

Moderate

Good studies show a real but usually modest benefit for many patients. Results vary from person to person.

Limited

Some studies and patient reports are encouraging, but the research is small, mixed, or short-term. Worth discussing; not guaranteed

Not Established

Research has not shown a benefit, or results so far have been negative. Cannabis may still ease related symptoms (such as sleep or appetite), but not the condition itself .

These ratings were checked against the medical literature as of October 2026. Research in this field moves quickly , and we will update this guide as new studies are published.

This guide is for education only. It is not medical advice and does not replace a visit with a qualified health care practitioner

Conditions at a Glance

Cannabis rarely works the same way for every symptom of a condition. A product can help one symptom and do nothing for another , and the type of product and how you take it matter. This table breaks each condition down by symptom.

People differ, too, and genes are part of the reason. In one study , people with two copies of a common variant of the liver enzyme CYP2C9 had about three times more THC in their blood after the same oral dose, with a trend toward more sedation (Sachse-Seeboth 2009). A variant of the AKT1 gene has been linked to a higher risk of psychosis among cannabis users, especially with daily use (Di Forti 2012).

Personalized testing with EndoDNA. That is why NYSOM works with EndoDNA, a genetic testing company , to give patients who want it a more personalized starting point. From a cheek swab, or from results you already have from a service like 23andMe or Ancestry, EndoDNA ‘s accredited lab looks at hundreds of thousands of genetic markers tied to the endocannabinoid system and to how your body processes medicines. Your report covers about 60 traits, including:

  • how quickly you are likely to break down THC and CBD
  • medications you take that may interact with THC or CBD
  • whether you may be more prone to side effects such as anxiety , a racing heart, or ,
  • rarely , psychosis-like reactions
  • traits related to sleep, mood, pain, and inflammation

We combine your EndoDNA results with your history , your medications, and how you actually respond, and a pharmacist reviews every recommendation. Genetic testing for cannabis is still being validated: the gene links come from published studies, but no trial has yet shown that choosing products by genetic results improves outcomes. Testing requires your written consent. NYSOM has a business partnership with EndoDNA.

Endo DNA

What was Studied

Condition Symptom or goal What was studied Evidence Bottom Line
ALS Muscle stiffness THC/CBD mouth spray Limited One small trial showed less stiffness.
ALS Slowing the disease — Not established No human evidence.
Alzheimer’s Agitation Prescription THC capsules Limited Two trials, one published in 2026, showed calmer behavior.
Alzheimer’s Memory and progression — Not established No evidence it protects memory.
Anxiety Social or performance anxiety Oral CBD Limited Small trials show some benefit.
Anxiety Daily anxiety THC Limited THC can make anxiety worse.
Appetite Weight loss with HIV/AIDS Prescription THC (dronabinol) Moderate FDA-approved for this use.
Appetite Weight loss with
cancer
THC, cannabis Not established No reliable weight gain shown.
Arthritis: osteoarthritis Joint pain Oral CBD Not established Three trials found no benefit over placebo.
Arthritis: osteoarthritis Joint pain in a small joint Topical CBD cream Limited One small thumb trial was positive. More trials under way.
Arthritis: rheumatoid Joint pain THC/CBD Limited Very small, short trials.
Arthritis: rheumatoid Joint damage — Not established Keep your rheumatology medicines.
Autism Disruptive behavior CBD-rich extract (20:1) Limited Mixed trial results.
Autism Core autism
traits
— Not established No evidence.
Cancer Treating the tumor — Not established Experts advise against.
Cancer Chemotherapy nausea Prescription THC; THC/CBD capsules Strong Helps when standard anti- nausea drugs are not enough.
Cancer Cancer pain THC/CBD spray,THC Not established Not better than placebo in trials.
Chronic pain Nerve-related pain THC or THC/CBD products Moderate Small to modest relief for some.
Chronic pain Chronic low back pain Standardized THC extract (oral) Moderate Large 2025 trial showed modest but meaningful relief.
Chronic pain Any pain CBD alone, swallowed Not established Trials mostly negative.
Crohn’s and colitis Pain, appetite, well-being Inhaled cannabis, oils Limited Some patients feel better.
Crohn’s and colitis Healing the gut — Not established No effect on inflammation shown.
Depression Low mood — Not established No trials; heavy use linked to worse mood.
Endometriosis Pelvic pain Inhaled THC, oral CBD Not established Trials could not enroll enough patients.
Epilepsy Lennox-Gastaut, Dravet, TSC Prescription CBD (Epidiolex) Strong Many patients have seizures cut by half or more.
Epilepsy Other seizure types Dispensary CBD or THC Not established Not studied the same way.
Fibromyalgia Pain and sleep Nabilone, THC products Limited Mixed results.
Glaucoma Eye pressure THC Not established Effect lasts only 3 to 4 hours.
HIV/AIDS Nerve pain Inhaled cannabis Moderate About half got meaningful relief .
Huntington’s Involuntary movements Nabilone; THC/CBD mouth spray Limited Mixed: one trial helped, one did not.
IBS Gut symptoms — Not established No good trials.
Migraine Stopping an attack Inhaled THC + CBD Limited One good trial was positive.
Migraine Stopping an attack CBD alone Not established Did not help in that trial.
Multiple sclerosis Muscle stiffness (spasticity) THC/CBD mouth spray Strong Approved in Canada and Europe.
Multiple sclerosis Nerve pain Oral THC products Moderate Modest relief.
Multiple sclerosis Bladder, sleep THC/CBD mouth spray Limited Early signals only.
Muscular dystrophy Stiffness (myotonia), pain Oral THC/CBD oil Limited Six-patient case series only.
Muscular dystrophy Slowing muscle loss — Not established Animal studies only.
Neuropathy Burning, tingling pain THC-containing products Moderate Modest relief for some.
Neuropathy Foot and leg nerve pain Topical CBD oil Limited One small positive trial.
Opioids Pain control compared with opioids Standardized THC extract (back pain) Limited One trial: similar pain relief , much less constipation.
Opioids Lowering opioid dose Various cannabis products Limited Patients report it; trials have not confirmed it.
Opioids Craving in opioid use disorder Oral CBD Limited One small trial reduced craving and anxiety .
Palliative care Appetite and weight in cancer THC, cannabis extract Not established Megestrol worked better in one trial.
Parkinson’s Tremor, movement, mood CBD , THC Not
established
Ten trials found no benefit.
PTSD Overall symptoms Smoked cannabis, CBD Not established Trials negative.
PTSD Nightmares Prescription THC (dronabinol, nabilone) Moderate A large 2026 trial found fewer, milder nightmares.
Sleep Insomnia on its own THC, CBD Limited Mixed results.
Sleep Sleep broken by pain THC-containing pain products Moderate Sleep improved in pain trials.
Spinal cord injury Muscle stiffness Prescription THC, nabilone Limited Small trials showed less stiffness.
Substance use Cannabis use disorder THC/CBD spray with counseling Limited Fewer days of use.
Substance use Opioid use disorder Cannabis, CBD Not established Not a substitute for buprenorphine or methadone.
Tourette
syndrome
Tics Oral THC/CBD oil Limited One small trial showed fewer tics.

Read the THC:CBD Ratio First

The ratio of THC to CBD matters more than anything else on the label. Most of the benefit and most of the side effects in trials track with the amount of THC.

Product Type Typical Ratio Best supported for Feels like
THC-dominant THC much higher than CBD Nausea, appetite, nerve pain, back pain, PTSD nightmares Most likely to cause a high, dizziness, or anxiety
Balanced About 1:1 MS stiffness, nerve pain, migraine attacks, Tourette, rheumatoid arthritis pain The high depends mainly on the THC dose
CBD-dominant 10:1 to 20:1 CBD to THC, or more Anxiety , prescription CBD for specific epilepsies Little or no high
CBD only No meaningful
THC
Topical use on a painful joint or nerve area No high

Swallowed CBD on its own has not relieved pain in controlled trials. If pain is the goal, products with some THC have the better evidence.

Minor Cannabinoids and Terpenes

Terpenes are the aroma compounds in cannabis. Products are often marketed by terpene or by “indica” and “sativa.” Large lab studies have shown the indica and sativa labels do not reliably predict what is in the product. Here is what human research shows so far:

Compound Common claim What human studies show Evidence
CBN Sleep In a 2024 placebo-controlled trial, 20 mg of CBN nightly for a week reduced nighttime awakenings and overall
sleep disturbance. It did not help people fall asleep faster. Adding CBD did not improve results.
Limited
CBG Calm, focus In a 2024 trial of 34 healthy adults, 20 mg of CBG reduced anxiety and stress and slightly improved memory, without impairment. Limited
THCV Blood sugar, appetite In a 2016 trial of 62 people with type 2 diabetes, THCV lowered fasting blood sugar. Appetite and weight effects are unproven. Limited
Limonene (citrus) Mood, calm In a 2024 Johns Hopkins study of 20 adults, inhaling limonene with THC reduced THC-caused anxiety and paranoia without blunting other THC effects. Limited
Linalool (lavender) Calm, sleep Lavender oil capsules rich in linalool reduced anxiety in 5 trials. Cannabis contains far less linalool, and it has not been tested in cannabis. Not established in cannabis
Eucalyptol (eucalyptus) Breathing, inflammation Capsules of eucalyptol, 200 mg three times a day, reduced COPD flare-ups and improved asthma control in trials. Cannabis contains only traces. Not established in
cannabis
Menthol (mint) Topical pain relief FDA recognizes menthol at 1.25% to 16% as an over-the-counter topical pain reliever . Many cannabis creams and balms add it. Proven as a topical (non-cannabis)
Camphor Topical pain relief FDA recognizes camphor at 3% to 11% as an over- the-counter topical pain reliever . Often combined with menthol. Proven as a topical (non-cannabis)
Myrcene (earthy) Sedation, “couch lock” No human trials. Not established
Beta-
caryophyllene (pepper)
Inflammation, pain Acts on CB2 receptors in the lab. No human pain trials. Not established
CBDV, CBC, THCA Seizures, inflammation, nausea Lab and animal data only. CBDV failed in a large seizure trial. Not established

 

If a cannabis cream or balm contains menthol or camphor , part of the relief you feel may come from those ingredients. Check the label.

The Physician Reference has a full condition-by-compound table with sources. Full list: all 125 cannabinoids and about 55 terpenes, with what is proven and what is not, are in the Cannabinoids & Terpenes tab.

A 2024 review concluded that terpenes boosting the effects of cannabinoids, the “entourage effect,” remains unproven in people. Terpene profiles are a reasonable tiebreaker between two products with the same THC:CBD ratio. They should not be the main reason to choose a product.

Choosing a Form

  • Fast relief for symptoms that come and go (migraine attack, breakthrough pain, nausea): inhaled flower , vaporized, or an under-the-tongue spray.
  • Steady all-day or overnight control (chronic pain, spasticity , sleep): capsules or oils taken on a schedule.
  • One or two painful joints or a small area of nerve pain: a topical, which puts very little into the bloodstream.

Using Cannabis Safely

Medical cannabis is generally well tolerated, but it is not risk-free. Knowing the risks helps you use it safely.

How the program developed

New York Program Basics

  • 2014: the Compassionate Care Act created New York’s medical program. Sales began in 2016 through a small number of Registered Organizations (ROs), companies licensed to grow, make, and dispense medical cannabis.
  • 2017 onward: chronic pain and PTSD were added, along with more product forms such as topicals, chewables, and lozenges.
  • 2021: the Marihuana Regulation and Taxation Act (MRTA) legalized adult use and created the Office of Cannabis Management (OCM), which now runs the medical program. Practitioners can now certify for any condition they believe cannabis may help.

As of October 1, 2026, the program had 69,031 registered patients and 4,820 certifying practitioners (OCM).

Medical, Adult-Use, Unregulated, and Hemp Products

Type Tested and labeled? Who you deal with Notes
Medical Yes, by a state-approved lab A pharmacist at a medical dispensary Requires a certification; no adult-use excise tax
Adult-use Yes Retail staff; no pharmacist required Age 21 and older; no clinician involved
Unregulated No Unknown Potency and contaminants unknown; linked to the 2019 vaping lung injuries
Hemp-derived CBD Varies General retail Studies often find labels inaccurate; some products contain THC

How to Get Certified

Caregivers

Certified patients can designate up to five registered caregivers to buy and help give medical cannabis on their behalf .

Cost and coverage

Health insurance does not cover medical cannabis, and purchases are cash or debit. Prices vary by product and dose, so ask the dispensary before you buy . Workers’ compensation is the exception: in New York, medical cannabis can be covered for a work- related injury . Ask your practitioner or the dispensary about the process.

Visiting New York

Patients enrolled in another state’s medical program can buy at New York medical dispensaries with their home-state documentation and photo ID . New York patients traveling elsewhere should check that state’s rules; many do not accept out-of-state cards. Never carry cannabis across state lines.

Home cultivation

Certified patients 18 and older , and their caregivers, may grow cannabis at home under OCM rules. Check OCM’s Home Grow guidance for plant limits and where to buy seeds.

Lab testing and labels

Every medical product is tested by a New York State–approved lab for cannabinoid content and contaminants. Labels show THC and CBD content and required warnings, and many list other cannabinoids such as CBG and CBN. Every manufacturer must offer balanced (1:1) and CBD-dominant (for example, 1:20 THC:CBD) products. THC-dominant products are sold at every dispensary and are the most commonly used.

Legal protections

New York law protects certified patients, caregivers, and practitioners who follow program rules. Federally , state-licensed medical cannabis moved to Schedule III in April 2026, but federal rules still apply on federal property and in federal workplaces. See OCM’s Patient Rights and Protections guide.

Product Forms and How Fast They Work

Form Starts working Lasts Good for Watch out for
Vaporized flower or oil Within minutes; peaks at about 9 minutes Up to about 2 hours Fast relief; easy to adjust the dose Throat and lung irritation; the state guideline advises against vaping, smoking, and dabbing
Smoked flower and pre-rolls Within minutes Similar to vaping Fast relief Smoke carries the most lung risk of any form; harder to measure the dose
Concentrates (wax, shatter, hash) Almost immediately 2 to 3 hours Experienced patients only Often above 60% THC; strong intoxication and risk of psychosis; very hot use creates irritants
Under the tongue (tinctures, sprays, lozenges) As early as 10 minutes Up to about 10 hours Small, adjustable doses; no inhaling; trouble swallowing Becomes a slower oral dose if swallowed
Swallowed (capsules, tablets, chewables, edibles, beverages) Peaks 1 to 5 hours after a dose Many hours, sometimes up to a day Steady overnight or all-day relief Easiest form to take too much of (see dose stacking); hardest to adjust
Topical and transdermal (creams, lotions, gels, patches) About 2 hours for transdermal products Up to 48 hours, depending on the product One painful area; people who cannot use other forms Absorption varies widely; products designed to reach the bloodstream can cause a high if they contain THC
Suppository 1 to 2 hours Up to about 8 hours When swallowing is not possible Very little research

 

Times come from the New York State Department of Health clinical guideline (October 2025) and vary from person to person and by product.

Start Low, Go Slow

  • New patients usually start with 2.5 mg of THC or less, often in the evening at home, as the state clinical guideline suggests.
  • Increase in small steps (about 1 to 2.5 mg) every few days, only if needed.
  • Avoid dose stacking: with edibles and capsules, wait at least 2 hours before taking more. Taking another dose before the first has worked is the most common cause of feeling too high.
  • Products with CBD and little THC are less likely to cause a high; many patients start there.
  • Check in with your practitioner or pharmacist 1 to 2 weeks after starting.
  • Keep a simple log of product, dose, time, and how you felt. Bring it to follow-up visits.
  • If you already use cannabis, the state guideline suggests starting medical cannabis at about half the THC you use now; ask the pharmacist which products match.

Questions to ask your practitioner:

  • What symptom are we trying to improve, and how will we know it is working?
  • Should I start with CBD , THC, or a mix?
  • Which form makes sense for my symptoms and schedule?
  • Do any of my current medicines interact with cannabis?
  • When should we check in, and when should I stop if it is not helping?

Glossary

Term Meaning
Bioavailability The share of a dose that reaches the bloodstream
Cannabinoid A compound that acts on the body’s cannabinoid receptors; THC and CBD are the best known
Cannabis use disorder Problem use: needing more, trouble cutting back, or use that interferes with daily life
Cannabinoid hyperemesis syndrome Repeated severe vomiting in some long-term heavy users; ends after stopping
CB1 and CB2 receptors The body’s two main cannabinoid receptors. CB1 is concentrated in the brain and nerves and drives the high; CB2 is found mainly on immune cells
Certification A practitioner’s documented recommendation that a patient may use medical cannabis
Certificate of analysis (COA) The lab report showing what a product contains
Designated caregiver A registered person who may buy and give medical cannabis for a patient
Dose stacking Taking another dose before the first has taken full effect
Endocannabinoid system The body’s own network of cannabinoid receptors and natural cannabinoid-like molecules
Morphine milligram equivalents (MME) A standard way to compare doses of different opioids
OCM The New York State Office of Cannabis Management
Reciprocity One state honoring another state’s medical cannabis enrollment
Registered Organization (RO) A company licensed in New York to grow, make, and dispense medical cannabis
Terpene An aroma compound in cannabis, such as limonene or myrcene
THC:CBD ratio The proportion of THC to CBD in a product
Titration Adjusting the dose gradually to find the lowest dose that works